--- title: "Omada Health (NASDAQ:OMDA) Price Target Raised to $24.00 at Barclays" description: "Barclays has raised its price target for Omada Health (NASDAQ:OMDA) from $21.00 to $24.00, maintaining an \"overweight\" rating. This suggests a potential upside of 20.60% from the current price. Other " type: "news" locale: "en" url: "https://longbridge.com/en/news/252338712.md" published_at: "2025-08-09T14:25:16.000Z" --- # Omada Health (NASDAQ:OMDA) Price Target Raised to $24.00 at Barclays > Barclays has raised its price target for Omada Health (NASDAQ:OMDA) from $21.00 to $24.00, maintaining an "overweight" rating. This suggests a potential upside of 20.60% from the current price. Other analysts have also provided positive ratings, with Goldman Sachs setting a target of $29.00 and Canaccord Genuity at $27.00. Omada Health's stock rose 2.3% to $19.90, with a consensus target price of $24.43. The company reported a revenue of $61.37 million but missed EPS estimates in its last quarterly results. Omada Health (NASDAQ:OMDA - Get Free Report) had its price objective raised by stock analysts at Barclays from $21.00 to $24.00 in a note issued to investors on Friday,Benzinga reports. The firm currently has an "overweight" rating on the stock. Barclays's target price would suggest a potential upside of 20.60% from the stock's current price. Several other analysts have also recently weighed in on the company. The Goldman Sachs Group began coverage on Omada Health in a report on Tuesday, July 1st. They set a "buy" rating and a $29.00 price objective for the company. JPMorgan Chase & Co. initiated coverage on Omada Health in a report on Tuesday, July 1st. They issued an "overweight" rating and a $19.00 price objective for the company. Wall Street Zen upgraded Omada Health to a "hold" rating in a research report on Monday, June 16th. Evercore ISI lifted their price objective on shares of Omada Health from $21.00 to $23.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 9th. Finally, Canaccord Genuity Group assumed coverage on shares of Omada Health in a report on Tuesday, July 1st. They issued a "buy" rating and a $27.00 price target for the company. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $24.43. **Get Our Latest Stock Report on Omada Health** ## Omada Health Stock Up 2.3% OMDA stock traded up $0.44 during trading on Friday, hitting $19.90. The company had a trading volume of 196,182 shares, compared to its average volume of 735,662. Omada Health has a fifty-two week low of $14.14 and a fifty-two week high of $28.40. Omada Health (NASDAQ:OMDA - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.22) EPS for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.07). The company had revenue of $61.37 million during the quarter, compared to analyst estimates of $55.17 million. ## Institutional Investors Weigh In On Omada Health Hedge funds and other institutional investors have recently made changes to their positions in the stock. Teacher Retirement System of Texas acquired a new stake in shares of Omada Health in the second quarter valued at about $640,000. Emerald Mutual Fund Advisers Trust bought a new position in Omada Health during the 2nd quarter worth approximately $2,950,000. Jennison Associates LLC bought a new position in Omada Health during the 2nd quarter worth approximately $4,580,000. Emerald Advisers LLC acquired a new position in shares of Omada Health in the 2nd quarter worth approximately $5,089,000. Finally, Sanofi bought a new stake in shares of Omada Health in the 2nd quarter valued at $9,606,000. ## Omada Health Company Profile (Get Free Report) Omada's mission is to bend the curve. Our hope is that, one day, tomorrow's epidemiologists will notice a bend in disease curves, wonder what might be happening, and conclude that part of that impact has been Omada. As part of that mission, we strive to inspire and enable people to make lasting health changes on their own terms. ## Read More - Five stocks we like better than Omada Health - Technology Stocks Explained: Here's What to Know About Tech - Why Axon's 16% Surge Signals a New Era in Public Safety Tech - What Makes a Stock a Good Dividend Stock? - DraftKings Posts Record Quarter, Eyes Profitability - What is diluted earnings per share (Diluted EPS)? - Amazon Takes an Equity Stake in IonQ—Any Upside Potential? *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.* ## Should You Invest $1,000 in Omada Health Right Now? Before you consider Omada Health, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omada Health wasn't on the list. While Omada Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [OMDA.US - Omada Health](https://longbridge.com/en/quote/OMDA.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Omada Health 首席執行官 Sean P. Duffy 報告了普通股的出售 | Omada Health Inc. 的首席執行官 Sean P. Duffy 報告了該公司普通股的處置。完整的文件可通過提供的鏈接獲取。此消息由 Public Technologies 生成，僅供參考，不應被視為財務或法律建議。Omada | [Link](https://longbridge.com/en/news/272612733.md) | | 揭開 Omada Health 的神秘面紗：7 位分析師的見解 | 7 位分析師對 Omada Health (NASDAQ:OMDA) 進行了評估，意見從看漲到看跌不一。最近的評級顯示情緒發生了變化，12 個月的平均目標價為 25.57 美元，低於之前的 26.80 美元。分析師對評級進行了各種調整，其中 | [Link](https://longbridge.com/en/news/272109717.md) | | 閃迪會成為下一個英偉達嗎？ | 閃迪從西部數據分拆出來以來，其股票自納斯達克迴歸以來已上漲超過 1500%。隨着對人工智能基礎設施需求的增長，閃迪專注於 DRAM 和 NAND 解決方案，使其在市場中處於有利位置。分析師預測強勁的盈利增長，前瞻市盈率為 15，表明其相較於 | [Link](https://longbridge.com/en/news/276063622.md) | | 期權熱點｜上周五 NBIS 大漲 9%，部分看漲期權飆升 378% | 美東時間 2026-02-13，Nebius 期權總成交 179098 張，看漲期權佔比 71%，看跌期權佔比 28%。 | [Link](https://longbridge.com/en/news/276030151.md) | | 對派拓網絡收益的預期 | 派拓網絡（NASDAQ:PANW）定於 2026 年 2 月 17 日發佈季度財報，分析師預計每股收益（EPS）為 0.76 美元。投資者對積極的指引抱有希望，尤其是在公司之前超出 EPS 預期後，股價卻隨之下跌了 7.42%。目前，股價為 | [Link](https://longbridge.com/en/news/276061399.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.